Journal
CURRENT DRUG TARGETS
Volume 21, Issue 9, Pages 855-863Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1389450121666200429114926
Keywords
Interleukin-37; inflammatory diseases; anti-inflammatory; cytokine; immune-mediated inflammatory; rheumatoid arthritis
Categories
Funding
- Scientific and Technological Advance Project of Hengyang City [2017KJ303]
- Key Lab for Clinical Anatomy & Reproductive Medicine of Hengyang City [2017KJ182]
- Undergraduate Research and Innovation Experimental Program of the University of South China [2018XJXZ161]
- Hunan Provincial Natural Science Foundation [2019JJ40250]
- Outstanding Youth Project of Hunan Education Department [18B262, 19B475]
Ask authors/readers for more resources
Interleukin-37 (IL-37) was discovered as a new member of pro-inflammatory IL-1 superfamily. However, further studies suggested that IL-37 plays a critical anti-inflammatory role in innate and adaptive immunity. IL-37 may suppress the inflammatory process via intracellular SMAD family member 3 (SMAD3) and extracellular IL-18 Receptor alpha (IL-18R alpha) signaling pathway, respectively. Meanwhile, the abnormal expression of IL-37 was observed in immune-mediated inflammatory diseases, such as inflammatory bowel disease, rheumatoid arthritis, atherosclerosis, systemic lupus erythematosus, asthma, and multiple sclerosis, which suggest IL-37 is a potential therapeutic target for these diseases. In this review, we summarize the anti-inflammatory mechanism of IL-37 and discuss the critical roles of IL-37 in the pathogenesis of these diseases. Further studies are required to confirm the effectiveness of IL-37 as a novel target for these inflammatory diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available